Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR6 | P51684 | 1/20 | 0.34 |
| ▸ | MITF | O75030 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | METAP1 | P53582 | 2/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6903785 | 0.79 | CES2 (0.32) | — | |
| SCHEMBL13899831 | 0.77 | — | — | |
| SCHEMBL5199186 | 0.77 | TLR4 (0.41) | CCR6MITFHSP90AA1METAP1ADRA2A | |
| SCHEMBL16564631 | 0.75 | CYP19A1 (0.32) | — | |
| SCHEMBL612141 | 0.75 | CYP19A1 (0.32) | — | |
| SCHEMBL8019882 | 0.73 | SIGMAR1 (0.35) | CCR6MITFHSP90AA1METAP1 | |
| Hydrochloric Acid SCHEMBL8615192 | 0.72 | CCR6 (0.35) | CCR6MITFHSP90AA1METAP1 | |
| SCHEMBL24340460 | 0.71 | NPC1 (0.34) | — | |
| SCHEMBL10562202 | 0.71 | BRD4 (0.35) | — | |
| SCHEMBL26615266 | 0.71 | NPC1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040162432-A1 | Substituted octahydrophenanthrene compounds and use thereof as NMDA antagonists | GRUNENTHAL GMBH (DE) | 2004-08-19 | — | — | US | disclosed |
| EP-1423353-A1 | SUBSTITUTED OCTAHYDROPHENANTHRENE COMPOUNDS AND THEIR USE AS NMDA ANTAGONISTS | Grünenthal GmbH (DE) | 2004-06-02 | — | — | EP | disclosed |
| WO-2003016261-A1 | SUBSTITUTED OCTAHYDROPHENANTHRENE COMPOUNDS AND THEIR USE AS NMDA ANTAGONISTS | Grünenthal GmbH (DE) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162432-A1 | Substituted octahydrophenanthrene compounds and use thereof as NMDA antagonists | GRIN3A, GRIN1, GRIN3B | CCR6 3695/4885MITF 689/4885HSP90AA1 4295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.